Table 5.

Comparison of psychological disorders during follow-up in statin users and non-users

	OR	95%CI		p-value
Propensity-matched patients
Psych1 (schizophrenia/other psychosis)	0.9	0.75	1.05	0.2
Psych2 (depression / bipolar disorder)	1.02	0.94	1.11	0.6
Psych3 (all psychological disorders)	1.02	0.96	1.1	0.5
All patients cohort*
Psych1 (schizophrenia/other psychosis)	0.9	0.78	1.06	0.2
Psych2 (depression / bipolar disorder)	1.03	0.95	1.11	0.5
Psych3 (all psychological disorders)	1.05	0.99	1.12	0.1
Patients with no Charlson comorbidity†
Psych1 (schizophrenia/other psychosis)	0.95	0.76	1.19	0.7
Psych2 (depression / bipolar disorder)	1.01	0.9	1.12	0.8
Psych3 (all psychological disorders)	1.03	0.95	1.05	0.5
Patients with no psychological disorders at baseline‡
Psych1 (schizophrenia/other psychosis)	0.88	0.72	1.08	0.2
Psych2 (depression / bipolar disorder)	0.97	0.89	1.07	0.6
Psych3 (all psychological disorders)	1.02	0.96	1.09	0.6

^*Adjusting for age, gender, statin use, all comorbid conditions as in table 2, total Charlson comorbidity score, obesity, smoking, alcohol use, illicit drug use, Psychological disorders at baseline, vision defects/blindness, number of all admissions in baseline period, number of all outpatients medical encounters in the baseline period, and use of different classes of medications as listed in table 1.

^†adjusting for the same factors mentioned earlier except for Charlson comorbidity total score and its components.

^‡adjusting for the same factors mentioned in “all patients cohort” except for “psychological disorders at baseline” covariate.